# ChainGen Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chaingen-bio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Series B (Dec 29, 2025)
- Investors on record: 7

## About

Based in Shanghai, China, and founded in 2021, Jiajin Biopharmaceutical (Shanghai) Co., Ltd, trading as Jiajin Biology, is a biotechnology company that focuses on drug coupling and delivery technologies. The founder and CEO, Hao Wu, graduated from Tsinghua University has worked for NGM, Novo Nordisk, WuXi Biologics, and other companies.  In December 2025, ChainGen Bio raised a series B+ funding from new investors Kangjun Capital, Yitan Investment, Legend Capital and returning investor YuanBio Venture.
The company specializes in the field of antibody-small nucleic acid coupled drugs and in-brain delivery which mainly develops drugs for genetic disorders of the neuromuscular system. The core pipeline focuses on two indications, DM1 and DMD. It has developed a brain-entry peptide Brainferry platform that can be applied in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
The company generates revenue by providing antibody-small nucleic acid coupled drugs and an in-brain delivery platform.
The series B+ round of financing will further support Jiajin Bio's investments in technology research and development, team building, and market expansion.

## Funding rounds

- Series B, Dec 29, 2025 — Legend Capital, YuanBio Venture, Kangjun Capital, Yitan Investment
- Series B, Aug 20, 2025 — Riverhead Capital
- Angel, Nov 9, 2022 — MPC, Frees Fund

## Investors

- MPC — Angel
- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Angel
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series B
- Legend Capital — Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- Kangjun Capital (https://capitalatlas.ai/funds/kangjun-capital) — Series B
- Yitan Investment (https://capitalatlas.ai/funds/yitan-investment) — Series B
